Table 2. Tumor response in patients with advanced NSCLC receiving S-1 as second-line or later therapy.
Items | Total (n=52), n (%) |
---|---|
PR | 15 (28.8) |
SD | 20 (38.5) |
PD | 17 (32.7) |
ORR | 15 (28.8) |
DCR | 35 (67.3) |
NSCLC, non-small cell lung cancer; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate.